Global Nuclear Medicine Market Size & Trends Report Segmented by Product (Diagnostics, Therapeutics), Application (Cardiology, Neurology, Oncology, Others), End-user (Hospitals, Diagnostic Centers, Others) & Regional Forecasts to 2030
The nuclear medicine market is projected to grow at a CAGR of 12% during the forecast period. Key drivers include the rising prevalence of cancer and cardiovascular diseases, increasing adoption of hybrid imaging systems, advancements in radiopharmaceuticals, and government investments in nuclear medicine research. However, restraints such as high costs of equipment and radiopharmaceuticals, regulatory hurdles, and limited availability of radioisotopes may hinder market growth. To learn more about the research report, download a sample report.
Report Overview
The nuclear medicine market involves advanced diagnostic and therapeutic methods utilizing radioactive substances to evaluate and treat a wide range of diseases. Central to these methods are radiopharmaceuticals and molecular imaging technologies, which provide precise insights into physiological processes and enable targeted treatment delivery. Predominantly applied in fields such as oncology, cardiology, and neurology, nuclear medicine offers non-invasive solutions for early disease detection and effective therapies. 
To learn more about the research report, download a sample report.
Rising Prevalence of Cancer and Cardiovascular Diseases
The increasing global burden of cancer and cardiovascular diseases significantly drives the demand for nuclear medicine. These conditions require precise diagnostic tools and effective treatment strategies, which nuclear medicine offers through its capability to visualize cellular-level changes and deliver targeted radiation therapy. According to WHO, cardiovascular diseases are the leading cause of death globally, claiming an estimated 17.9 million lives annually as of 2019. Similarly, the International Agency for Research on Cancer reported nearly 20 million new cases of cancer in 2022, along with 9.7 million cancer-related deaths. Nuclear imaging modalities, such as PET and SPECT, are vital in the early detection, staging, and monitoring of these conditions. Radiopharmaceutical therapies, such as theranostics, provide tailored treatment options that improve outcomes. As awareness grows among healthcare professionals and patients, nuclear medicine adoption continues to rise, ensuring timely interventions and better prognosis for life-threatening diseases. 
To learn more about the research report, download a sample report.
Next-Generation Radiopharmaceuticals: Enhancing Diagnostics and Therapy
The introduction of innovative radiopharmaceuticals is reshaping the nuclear medicine market by expanding its scope in diagnostics and therapeutics. Novel isotopes, such as Lutetium-177 and Actinium-225, are being developed for targeted radioligand therapy, offering precise cancer treatment with minimal damage to healthy tissues. On the diagnostic side, fluorine-based tracers and other innovative molecules enhance imaging capabilities for conditions like Alzheimer’s disease and neuroendocrine tumours. Significant investments in research and collaborations between pharmaceutical companies and academic institutions drive these advancements. By addressing limitations in existing isotopes and expanding therapeutic applications, these novel radiopharmaceuticals are making nuclear medicine more effective and accessible. This progress is fostering the adoption of personalized treatment approaches, improving patient outcomes, and fueling market growth.
Competitive Landscape Analysis
The global nuclear medicine market is marked by the presence of established and emerging market players such as GE Healthcare; Jubilant Life Sciences Ltd; Nordion, Inc.; Bracco Imaging S.P.A; The Institute for Radioelements (IRE); NTP Radioisotopes SOC Ltd.; The Australian Nuclear Science and Technology Organization; Eczacıbaşı-Monrol; Lantheus Medical Imaging, Inc; Eckert & Ziegler; Mallinckrodt; and Cardinal Health among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Report Scope
| Report Scope | Details |
| Base Year Considered | 2024 |
| Historical Data | 2023-2024 |
| Forecast Period | 2025-2030 |
| Growth Rate | 12% |
| Market Drivers |
|
| Attractive Opportunities |
|
| Segment Scope | Product, Application and End-user |
| Regional Scope |
|
| Key Companies Mapped | GE Healthcare; Jubilant Life Sciences Ltd; Nordion, Inc.; Bracco Imaging S.P.A; The Institute for Radioelements (IRE); NTP Radioisotopes SOC Ltd.; The Australian Nuclear Science and Technology Organization; Eczacıbaşı-Monrol; Lantheus Medical Imaging, Inc; Eckert & Ziegler; Mallinckrodt; and Cardinal Health among others |
| Report Highlights | Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Market Segmentation
This report by Medi-Tech Insights provides the size of the nuclear medicine market at the regional- and country-level from 2023 to 2030. The report further segments the market based on product, application and end-user.
- Market Size & Forecast (2023-2030), By Product, USD Million
- Diagnostics
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Others
- PET
- F-18
- SR-82/RB-82
- PYLARIFY (piflufolastat F 18)
- Illuccix (gallium Ga 68 gozetotide)
- Others
- Therapeutics
- Alpha Emitters
- RA-223
- Others
- Beta Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-177
- Others
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Others
- Diagnostics
- Market Size & Forecast (2023-2030), By Application, USD Million
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Pulmonary Scans
- Urology
- Other
- Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic Centers
- Others
- Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
- North America
Key Strategic Questions Addressed
- What is the market size & forecast of the nuclear medicine market?
- What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the nuclear medicine market?
- What are the key trends defining the market?
- What are the major factors impacting the market?
- What are the opportunities prevailing in the market?
- Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
- Who are the major players operating in the market?
- What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2025-2026)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Nuclear Medicine Market Snapshot (2025-2030)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Increasing incidence of chronic diseases
- Rising demand for early and accurate diagnostic solutions in healthcare
- Growing preference for non-invasive diagnostic and therapeutic techniques
- Increasing adoption of hybrid imaging systems
- Expanding applications in personalized medicine and neurology
- Restraints
- High cost of nuclear imaging equipment and radiopharmaceuticals
- Stringent regulatory requirements for approval of isotopes and procedures
- Limited availability and short half-life of radioisotopes
- Opportunities
- Development of next-generation radiopharmaceuticals for emerging therapeutic applications
- Miniaturization of imaging systems for portable and cost-effective solutions
- Growing government investments and support for nuclear medicine research
- Key Market Trends
- Integration of AI in nuclear imaging for enhanced precision and efficiency
- Introduction of novel isotopes like Actinium-225 and Lutetium-177 for targeted therapies
- Unmet Market Needs
- Industry Speaks
- Global Nuclear Medicine Market Size & Forecast (2023-2030), By Product USD Million
- Introduction
- Diagnostics
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Others
- PET
- F-18
- SR-82/RB-82
- PYLARIFY (piflufolastat F 18)
- Illuccix (gallium Ga 68 gozetotide)
- Others
- Therapeutics
- Alpha Emitters
- RA-223
- Others
- Beta Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-177
- Others
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Others
- Alpha Emitters
- SPECT
- Global Nuclear Medicine Market Size & Forecast (2023-2030), By Application USD Million
- Introduction
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumour
- Pulmonary Scans
- Urology
- Other
- Global Nuclear Medicine Market Size & Forecast (2023-2030), By End-user USD Million
- Introduction
- Hospitals
- Diagnostic Centers
- Others
- Global Nuclear Medicine Market Size & Forecast (2023-2030), By Region, USD Million
- Introduction
- North America Nuclear Medicine Market Size & Forecast (2023-2030), By Country, USD Million
- US
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Canada
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- US
- Europe Nuclear Medicine Market Size & Forecast (2023-2030), By Country, USD Million
- UK
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Germany
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Italy
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Spain
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Europe
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- UK
- Asia Pacific (APAC) Nuclear Medicine Market Size & Forecast (2023-2030), By Country, USD Million
- China
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Japan
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- India
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- China
- Latin America (LATAM) Nuclear Medicine Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Middle East & Africa (MEA) Nuclear Medicine Market Size & Forecast (2023-2030), USD Million
- Market Size & Forecast, By Product (USD Million)
- Market Size & Forecast, By Application (USD Million)
- Market Size & Forecast, By End-user (USD Million)
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2024)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2024)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*(Business Overview, Financial Performance**, Products Offered, Recent Developments)
-
- GE Healthcare
- Jubilant Life Sciences Ltd
- Nordion, Inc.
- Bracco Imaging S.P.A
- The Institute for Radioelements (IRE)
- NTP Radioisotopes SOC Ltd.
- The Australian Nuclear Science and Technology Organization
- Eczacıbaşı-Monrol
- Lantheus Medical Imaging, Inc
- Eckert & Ziegler
- Mallinckrodt
- Cardinal Health
- Other Prominent Players
Note: *Indicative list
**For listed companies
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Stakeholders from Hospitals, Diagnostic Centers and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
